Metformin sensitizes AML cells to venetoclax through endoplasmic reticulum stress— CHOP pathway
British Journal of Haematology · 2023
DOI: 10.1111/bjh.18968 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Haematology, 2023. Verfasst von Lei Hua und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, China. Hauptthemen laut MEDLINE: Metformin, Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 50 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Venetoclax inhibits acute myeloid leukaemia by inhibiting BCL‐2 targeting, and a combination regimen with venetoclax has been explored. Although these regimens produce better clinical results, the vast majority of patients still suffer from disease recurrence or primary drug resistance. Metformin has been demonstrated to induce apoptosis in cancer cells. However, whether it can synergize with venetoclax and the underlying mechanisms of metformin‐induced apoptosis are not fully understood. In this study, we investigated the effect of metformin and venetoclax on the growth of AML cells in vitro and in vivo . In both Molm13 and THP‐1 cell lines, metformin and venetoclax synergistically inhibited the proliferation and induced apoptosis of leukaemia cells. Most importantly, the combination of metformin and venetoclax treatment significantly increased the expression levels of the endoplasmic reticulum (ER) stress‐related marker CHOP, for example, in AML cell lines. Knockdown of CHOP markedly attenuated the metformin‐ and venetoclax‐induced cell apoptosis. Moreover, the combination of metformin and venetoclax demonstrated prominent anti‐leukaemia effects in xenograft models and bone marrow samples from AML patients. In summary, the combination of metformin and venetoclax showed enhanced anti‐leukaemia activity with acceptable safety in AML patients, representing a new combinatorial strategy worth further clinical investigation to treat AML.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, China.
ORCID-Profile: Kexiu Huang, Hui Zeng
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Hua, L., Yang, N., Li, Y., Huang, K., Jiang, X., Liu, F., Yu, Z., Chen, J., Lai, J., Du, J., & Zeng, H. (2023). Metformin sensitizes AML cells to venetoclax through endoplasmic reticulum stress— CHOP pathway. British Journal of Haematology. https://doi.org/10.1111/bjh.18968
Vancouver
Hua L, Yang N, Li Y, Huang K, Jiang X, Liu F, et al. Metformin sensitizes AML cells to venetoclax through endoplasmic reticulum stress— CHOP pathway. British Journal of Haematology. 2023. doi:10.1111/bjh.18968
BibTeX
@article{Hua2023,
author = {Hua, Lei and Yang, Nianhui and Li, Yue and Huang, Kexiu and Jiang, Xinya and Liu, Fangshu and Yu, Zhi and Chen, Jie and Lai, Jing and Du, Juan and Zeng, Hui},
title = {Metformin sensitizes AML cells to venetoclax through endoplasmic reticulum stress— CHOP pathway},
journal = {British Journal of Haematology},
year = {2023},
doi = {10.1111/bjh.18968}
}
EUVIMED